Molecular profile linked to resistance to hypomethilating agents plus venetoclax does not predict outcome in secondary Acute Myeloid Leukemia patients receiving CPX-351 induction.
Observational analysis shows overall survival in secondary AML not linked to HMA-VEN resistance or somatic mutations, suggesting CPX-351 may help fit patients.
Key Points
CR rate and MRD negative CR probability were not affected by high-risk mutations or resistance profiles.
Median overall survival was noted at 15 months, with 1-year rates at about 52.7%.
Assessment using next-generation sequencing on bone marrow samples evaluated critical mutations for prognostic impacts.
Hematopoietic stem cell transplantation improved outcomes significantly, with MRD-negative status correlating with better survival.